CBMG announced a manufacturing collaboration agreement with Novartis at the end of last month to produce CAR-T treatment Kymriah for the Chinese market and the company has further ambitions in the pipeline.
AGC Biologics has announced plans to build a mammalian cell culture facility in Japan, where the company says demand is growing for antibody-based therapies.
Daiichi Sankyo announced it has entered into a clinical trial collaboration agreement with Merck & Co. to evaluate an investigational lung cancer treatment.
Alexion has agreed to pay up to $1.2bn for Syntimmune and its lead asset SNT001, a monoclonal antibody designed to treat warm autoimmune haemolytic anaemia.
Novo Nordisk will take over the lease of a manufacturing facility in Fremont, California, where the company will make stem cell-based therapies with optionally licensed technology.
Think of big biotech hubs in the US and two areas will immediately come to mind: Boston, on the east coast, and San Francisco, on the west – Los Angeles wants to change that.
Halozyme Therapeutics announced that a subcutaneous formulation of trastuzumab created with Halozyme’s technology, for the treatment of breast cancer, has received approval from Health Canada.
